GlaxoSmithKline (GSK), Tres Cantos Medicines Development Campus (TCMDC), Madrid, Spain, is building on an open-innovation strategy. They began with the publication of their antimalarial compound set and now they have screened their entire pharmaceutical library of more than two million compounds to find any compound that can inhibit tuberculosis (TB).
Lluís Ballell and colleagues describe the structure, anti-tubercular properties, and drug-like profile of 177 promising “hits” that will be made available to researchers. Ballell’s team envisages that the release of such anti-TB screening sets will enable the creation of a virtual community of scientists engaged in drug discovery efforts toward addressing neglected diseases.
- Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis,
L. Ballell, R. H. Bates, R. J. Young, D. Alvarez-Gomez, E. Alvarez-Ruiz, V. Barroso, D. Blanco, B. Crespo, J. Escribano, R. González, S. Lozano, S. Huss, A. Santos-Villarejo, J. J. Martín-Plaza, A. Mendoza, M. J. Rebollo-Lopez, M. Remuiñan-Blanco, J.-L. Lavandera, E. Pérez-Herran, F. J. Gamo-Benito, J. F. García-Bustos, D. Barros, J. P. Castro, N. Cammack,
ChemMedChem 2013, 8 (02).
DOI: 10.1002/cmdc.201200428
